Abbott Laboratories

NYSE: ABT
$113.73
-$0.42 (-0.4%)
Real Time Data Delayed 15 Min.

ABT Articles

The three major U.S. stock indexes opened lower this morning, and never really got untracked all day. Spanish 10-year bond yields fell 28 basis points to around 5.51%, while Spain again demurred on...
Abbott Laboratories (NYSE: ABT) said that third-quarter earnings surged, despite a slip in revenue, due to a double-digit decline in expenses. The health care company posted adjusted earnings per...
The three major U.S. stock indexes opened higher this morning following a report that economic sentiment in Germany came in better than expected (more coverage here) and that U.K. inflation was lower...
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday. Abbott Laboratories (NYSE: ABT) cut to Market Perform at Leerink Swann....
The quarterly ExpertRECALL Index released today indicates that more than 123 million medical device units were recalled during the second quarter of 2012, an eight-quarter high. The medical device...
The press recently had a field day with a report from the “Institute for Policy Studies” about executive pay. The report said the of the 100-highest paid U.S. CEOs in 2011, “26 took home more...
Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug. Amarin Corp. (NASDAQ: AMRN) announced approval by the FDA for Vascepta to...
At the end of two weeks of non-stop second quarter earnings reports, S&P Capital IQ expects a decline of -0.71% year-over-year in the S&P 500 Index for the quarter, a figure it calls...
The three major US stock indexes opened modestly lower this morning as there was little news out of Europe and Asian markets closed mixed. Traders were waiting to hear more from Fed Chairman Bernanke...
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers...
Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported...
The three major US stock indexes opened higher this morning in advance of Fed Chairman Ben Bernanke’s semi-annual report to Congress and following some data on inflation (more coverage here),...
Wednesday is going to mark yet another important day for the early wave of key earnings for this earnings season.  The second quarter became more challenging for many companies as we noted about so...
News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment has the entire drug sector up in arms as it pertains to...